New Drug Could Transform Pancreatic Cancer Treatment
Halozyme Therapeutics, Inc. (NASDAQ: HALO) has developed a new drug called PEGPH 20, which is changing the way pancreatic cancer patients are treated.
Helen Torley, Halozyme Therapeutics CEO, was on CNBC Monday to shed more light on the drug and the success it has had.
"Some patients with pancreatic cancer have a sugar; it is around the cells and between the cells and it creates a barrier to cancer therapies being able to get to the cancer to work," Torley began.
"So, our drug, which is called PEGPH 20, breaks down that sugar and it basically allows the cancer therapies you are giving with it to get access to where it needs to work."
Torley was asked what success rate PEGPH 20 has had on pancreatic cancer patients during trials. She replied, "We have just reported our results from our phase-II study; they are interim results. In that study it looked like about 50 percent of patients had high levels of this sugar called hyaluronan and in those patients, the time for the patients to progress was about 9 month, now that— when they [...] received our drug.
"For the patients who didn't receive our drug, they progressed in about 4 months. So, that really, for pancreatic cancer patients who have a median survival of just 6 months, is exciting and encouraging data."
On the drug's potential price tag, Torley said, "We haven't got a price yet. We are just entering our phase III studies. We will begin that in the beginning of 2016."
Image Credit: Public Domain
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.